 |
|
|  |
Thesis Chemistry, LLC.
Contact @ Thesis Chemistry, LLC
John R. Peterson, CEO & President
Phone: +1 216 229 1640
Fax: +1 216 229 1641
E-mail: jpeterson@thesischemistry.com
Web: www.thesischemistry.com |
Contact @ Daicel Chemical Industries, Ltd.
Takeshi Matsumoto, Ph.D.
General Manager, CPI Company
Phone: +81 3 3507 3190
Fax: +81 3 3507 3198
E-mail: tk-matsu@daicel.co.jp
Web: www.daicel.co.jp/cpi/ |
NEWS RELEASE
THESIS CHEMISTRY AND DAICEL CHEMICAL INDUSTRIES ANNOUNCE A COLLABORATIVE BUSINESS DEVELOPMENT AGREEMENT FOR CHIRAL PROCESS MANUFACTURING
CLEVELAND, OHIO and TOKYO, JAPAN – August 12, 2003 - Thesis Chemistry, LLC (Thesis), and Daicel Chemical Industries, Ltd. (Daicel), announce a Collaborative Business Development Agreement wherein Daicel's CPI Company will provide custom manufacturing and biotransformation services related to Thesis' third-party projects.
"Our agreement with Daicel fulfills Thesis' commitment to provide our customers with integrated chemical development services supporting pre-clinical to commercial supply of pharmaceutical chemicals," says Dr. John R. Peterson, Chief Executive Officer and President of Thesis Chemistry. "We carefully selected our manufacturing partner so as to complement the offerings of our existing industry partners and to be able to match our customer's project requirements with the broadest spectrum of commercial-scale processing technologies for production of single-handed (chiral) fine chemicals and pharmaceuticals. Daicel's technologies in organic synthesis, enzymatic biotransformations and chromatographic separations are geared towards the manufacture of chiral pharmaceutical chemicals in quantities up to multi-metric tons."
"Daicel is pleased to partner with Thesis Chemistry and provide its customers with custom manufacturing and development services related to our core technologies for producing chiral pharmaceutical chemicals", says Dr. Takeshi Matsumoto, General Manager, Daicel Chemical Industries, CPI Company. "In particular, we normally rely on SMB chromatography and biotransformations to obtain the best economic and technical solution for a customer's chiral process."
Thesis Chemistry, LLC manages and provides chemical development services to the pharmaceutical, animal health and generic drug industries. The Company links its process development capabilities and familiarity with the regulatory requirements of drug manufacture with the resources of its industry partners for contract supply of developmental quantities of pre-clinical and clinical drugs, custom manufacture of bulk substance and sourcing of raw materials and process intermediates used in the manufacture of drugs. Thesis has established agreements with Chiral Technologies, Inc. (a subsidiary of Daicel) for chiral separations, Regis Technologies, Inc. for production of preclinical and clinical drugs and intermediates, and with Major Chemicals Co., Ltd. and S. Amit & Co. for economical sourcing of raw materials and early processing intermediates from China and India, respectively.
Daicel Chemical Industries, Ltd., with headquarters in Japan, is a global chemical manufacturer with consolidated sales over $2 billion. Daicel was established in 1919 through a merger of eight celluloid companies, under the name Dainippon Celluloid Co., Ltd. The company's growth includes various cellulosic derivatives, organic chemicals, plastics, film, airbags, and chiral chromatography. The CPI Company division offers a wide range of organic syntheses combined with biotechnologies and integrated chiral technologies for the pharmaceutical and agrochemical industries. Today, Daicel supplies chiral synthons and custom manufactures intermediates and bulk actives under cGMP and ISO standards from investigational to commercial scale. SMB, a form of industrial scale chromatographic separation, and bioreactions (biotransformation) using a variety of microbes including recombinant bacteria are core technologies that Daicel uses to introduce chirality into a fine chemical.
Thesis Chemistry, LLC
…"powering pharmaceutical research and development through creative chemistry"ä …
|
|
|
